Advancing the state of the art of precision medicine to dramatically improve the lives of people with cancer
Oncologie, Inc., is advancing a new paradigm of precision oncology with an RNA-based approach to identify the dominant biology of cancers, particularly in the solid tumor microenvironment. A deep understanding of how to prospectively identify patients based on their dominant biology has allowed Oncologie to search for and obtain clinical-stage therapies that address these biologies, and further develop them into breakthrough therapies.
Predictive biomarkers historically worked on single-driver mutations yet only 10% of people with cancer have known driver mutations with available targeted therapies. Oncologie is advancing a new paradigm of precision oncology with an RNA-based approach that identifies a larger number of genes associated with the dominant biology of the tumor microenvironment (TME) within cancer patients.
Navicixizumab is an investigational bi-specific antibody that inhibits the activity of both vascular endothelial growth factor A (VEGF-A) and delta-like ligand 4 (DLL4), two pathways identified in playing a role in tumor progression.